Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

NCT04300309 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
28
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals

Collaborators